Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23087148 | 1.00 | HCAR2 (0.46) | HCAR2NFE2L2KEAP1TSHRALDH1A1 | |
| SCHEMBL518574 | 0.74 | — | — | |
| SCHEMBL6282254 | 0.73 | ALDH1A1 (0.42) | HCAR2NFE2L2KEAP1TSHRALDH1A1 | |
| SCHEMBL6282256 | 0.73 | ALDH1A1 (0.42) | HCAR2NFE2L2KEAP1TSHRALDH1A1 | |
| SCHEMBL1082447 | 0.72 | — | — | |
| SCHEMBL873013 | 0.70 | TSHR (0.42) | HCAR2NFE2L2KEAP1TSHRALDH1A1 | |
| SCHEMBL620969 | 0.70 | — | — | |
| SCHEMBL11726683 | 0.69 | TSHR (0.49) | HCAR2NFE2L2KEAP1TSHRALDH1A1 | |
| SCHEMBL106091 | 0.69 | TSHR (0.41) | HCAR2NFE2L2KEAP1TSHRALDH1A1 | |
| SCHEMBL15965602 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11554365-B2 | Organoruthenium carbide complexes as precatalysts for olefin metathesis | APEIRON SYNTHESIS S.A. (PL) | 2023-01-17 | — | — | US | disclosed |
| US-20220176362-A1 | ORGANORUTHENIUM CARBIDE COMPLEXES AS PRECATALYSTS FOR OLEFIN METATHESIS | Apeiron Synthesis S. A. (PL) | 2022-06-09 | — | — | US | disclosed |
| US-11291983-B2 | Organoruthenium carbide complexes as precatalysts for olefin metathesis | APEIRON SYNTHESIS S.A. (PL) | 2022-04-05 | — | — | US | disclosed |
| US-20210077988-A1 | ORGANORUTHENIUM CARBIDE COMPLEXES AS PRECATALYSTS FOR OLEFIN METATHESIS | Apeiron Synthesis S. A. (PL) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11554365-B2 | Organoruthenium carbide complexes as precatalysts for olefin metathesis | RCOR1, NFE2L2, ARL1 | HCAR2 1718/4885NFE2L2 2/4885KEAP1 74/4885 |
| US-20220176362-A1 | ORGANORUTHENIUM CARBIDE COMPLEXES AS PRECATALYSTS FOR OLEFIN METATHESIS | RCOR1, NFE2L2, ARL1 | HCAR2 1718/4885NFE2L2 2/4885KEAP1 74/4885 |
| US-20210077988-A1 | ORGANORUTHENIUM CARBIDE COMPLEXES AS PRECATALYSTS FOR OLEFIN METATHESIS | RCOR1, OXER1, ARL1 | HCAR2 1759/4885NFE2L2 4/4885KEAP1 76/4885 |
| US-11291983-B2 | Organoruthenium carbide complexes as precatalysts for olefin metathesis | RCOR1, OXER1, ARL1 | HCAR2 1759/4885NFE2L2 4/4885KEAP1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.